Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic...

Area of Science:

• Oncology
• Biochemistry
• Urology

Background:

• Prostate cancer diagnosis and monitoring rely on tumor markers like prostate-specific antigen (PSA).
• Distinguishing benign prostatic conditions from prostate cancer requires accurate diagnostic tools.
• Tissue polypeptide-specific antigen (TPS) is a marker of cell proliferation.

Purpose of the Study:

• To compare the diagnostic utility of TPS and PSA in prostate cancer.
• To evaluate the role of TPS in differentiating benign prostatic hypertrophy (BPH) from prostate cancer.
• To assess the correlation of TPS and PSA with disease progression and metastatic activity.

Main Methods:

• Serum concentrations of TPS and PSA were measured in patients.
• Patient groups included those with benign prostatic hypertrophy (BPH), active prostate cancer, and inactive prostate cancer.
• Tumor marker levels were analyzed in relation to disease status and metastatic progression.

Main Results:

• PSA was elevated in 50% of BPH patients, 88% with active cancer, and 40% with inactive cancer.
• TPS showed lower elevations: 6% in BPH, 34% in active cancer, and 0% in inactive cases.
• Metastatic progression correlated with significant increases in both PSA and TPS levels.

Conclusions:

• TPS may serve as a valuable adjunct marker in prostate cancer diagnosis and follow-up.
• TPS can potentially aid in differentiating benign prostatic conditions from malignant disease.
• Combined assessment of PSA and TPS may improve diagnostic accuracy and disease monitoring in prostate cancer.